Biotechnology company
Appears in 1 story
Sponsor of the KOALA trial
HaemaLogiX dosed the first patient in its Phase 1 KOALA trial on August 26, and the infusion was well tolerated with no serious adverse events. A second patient is enrolled and set to receive a higher dose at Melbourne's Peter MacCallum Cancer Centre.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
